Key Takeaways
- There's no single PT-141 dose. Your clinician sets your dose and directions.
- The only FDA-approved bremelanotide product is Vyleesi, a 1.75 mg single-dose autoinjector labeled for acquired, generalized low sexual desire in premenopausal women.
- Compounded PT-141 is not FDA-approved and is prescribed off-label.
- Before prescribing, a clinician needs your blood pressure, heart history, and full medication list.
- Nausea is the most common side effect, reported by 40% of people in the Vyleesi trials.
There's no single PT-141 dosage. Vyleesi is the only FDA-approved form, and for compounded PT-141, the dose on your prescription label is the only one that applies to you.
PT-141 is the development name for bremelanotide, a synthetic peptide that activates melanocortin receptors. Beyond the approved injection, a clinician can prescribe compounded needle-free PT-141 formats such as troches, sublingual strips, and nasal sprays.
How PT-141 works
PT-141 acts in the brain rather than on blood flow, and the approved label is clear about what is and isn't known.
- Bremelanotide activates the melanocortin receptor. MC4R neurons sit throughout the central nervous system (including the hypothalamus and medial preoptic area); their activation triggers dopamine release to enhance sexual desire, arousal, and intimacy.
- The FDA label states that the mechanism by which bremelanotide improves low desire is unknown.
- PDE5 inhibitors such as Viagra and Cialis work differently, by increasing blood flow to the penis.
PT-141 formats and strengths
Every Rebody PT-141 format is needle-free. Vyleesi is included for reference only and isn't offered by Rebody. The table lists product facts only; your clinician chooses the format and sets the directions.
| Format | FDA status | Strength and package | Who sets the dose |
|---|---|---|---|
| Vyleesi autoinjector | FDA approved | 1.75 mg in 0.3 mL, single-dose autoinjector | Set by prescriber per FDA label |
| PT-141 troches | Compounded, off-label | 2 mg; 8 mini troches per package | Your clinician, on your prescription label |
| PT-141 strips | Compounded, off-label | 2 mg; 24 per package | Your clinician, on your prescription label |
| PT-141 nasal spray | Compounded, off-label | 5 mg/mL in a 3 mL bottle | Your clinician, on your prescription label |
| PT-141 + oxytocin dissolving tablets | Compounded, off-label | 1 mg PT-141 + 20 IU oxytocin, or 2 mg + 40 IU; 8 per package | Your clinician, on your prescription label |
Current prices are on each product page. The PT-141 nasal spray vs. troche guide covers the practical differences between the two most common formats.
PT-141 for women: the approved product and off-label use
For premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), the reference product is Vyleesi, the FDA-approved 1.75 mg bremelanotide autoinjector.
In two identical 24-week phase 3 trials in 1,247 premenopausal women, Vyleesi improved sexual desire and reduced distress about low desire compared with placebo, according to the FDA label.
Vyleesi is not indicated for postmenopausal women, for men, or to enhance sexual performance. Compounded PT-141 for any woman is prescribed off-label, and a clinician chooses the format and strength after reviewing her history.
PT-141 for men: what the research tested
Vyleesi is not indicated for men, so there is no FDA-labeled male dose. What exists is early research, in small groups, using research formulations:
- An intranasal study in 30 healthy men and 24 men with mild-to-moderate erectile dysfunction (ED) who responded to Viagra found statistically significant erectile responses versus placebo.
- A study of injected PT-141 in 48 healthy men and 25 men with ED who had an inadequate response to Viagra also found statistically significant erectile responses versus placebo, measured with a RigiScan device.
Neither study tested a compounded troche, strip, or spray, so the results don't carry over to those formats. For men, compounded PT-141 is prescribed off-label, and a clinician decides whether it fits after reviewing your history.
Side effects and safety
In the Vyleesi trials, most side effects were mild or moderate and passed on their own. These rates come from the approved injection in premenopausal women with HSDD; rates for compounded formats haven't been studied.
- Common reactions: nausea (40%), flushing (20%), reactions where the injection was given (13%), and headache (11%). About 13% needed anti-nausea medicine, and 8% stopped because of nausea.
- Blood pressure and heart rate: systolic pressure rose by up to 6 mmHg and heart rate fell by up to 5 beats per minute, usually back to baseline within 12 hours.
- Skin darkening: reported in about 1% of trial patients, and more often with more frequent use and in people with darker skin.
- Other medicines: bremelanotide can change how some oral medicines are absorbed, including naltrexone and indomethacin.
The approved label is contraindicated in uncontrolled high blood pressure and known cardiovascular disease, and it advises effective contraception during use.
Formats with oxytocin aren't for anyone who is or could be pregnant, because oxytocin can make the uterus contract. Get urgent care for hives, swelling, trouble breathing, chest tightness, or fainting.
What to ask any PT-141 provider
Compounded PT-141 has no brand-name version, so the meaningful differences are in the care. Before starting, ask:
- Does a licensed clinician review my blood pressure, heart history, and medications before prescribing?
- Is the medication prepared by a licensed U.S. 503A compounding pharmacy, with my name and strength on the label?
- Is it clear which products are FDA-approved and which are compounded?
- Can I message my care team about side effects or switching formats?
Rebody's PT-141 is prepared by a licensed U.S. 503A compounding pharmacy and shipped free, and the price covers the visit, the provider review, and delivery.
Getting your PT-141 dose set by a clinician
The right PT-141 dose comes from your history, not a chart. With Rebody, a licensed U.S. clinician reviews your goals, blood pressure, heart history, and medications.
A licensed U.S. 503A pharmacy prepares the format and strength you're prescribed, and your care team adjusts the plan as you report back.
Start an online visit to see which PT-141 format fits you.
Frequently Asked Questions (FAQs)
Is PT-141 the same as Vyleesi?
Both contain bremelanotide. Vyleesi is the FDA-approved autoinjector for acquired, generalized low sexual desire in premenopausal women. Compounded PT-141 is a different product and doesn't carry that approval or indication.
How is PT-141 different from Viagra?
PT-141 activates melanocortin receptors in the brain, which are linked to desire and arousal. Viagra is a PDE5 inhibitor that works by increasing blood flow to the penis.
Is compounded PT-141 FDA-approved?
No. Compounded medications are not FDA-approved. They're prepared by a licensed pharmacy for an individual patient's prescription after a clinician's review.
How do prescription peptides differ from laboratory-only products?
laboratory-only (laboratory-only) peptides are intended strictly for laboratory research and are not for human use. Prescription peptides are reviewed and prescribed by licensed clinicians, then filled and dispensed by licensed U.S. pharmacies with directions for your specific treatment.
This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your health or before changing treatment. Do not delay medical care because of something you read here.